

AMENDMENTS TO THE CLAIMS

This Listing of the Claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims

1-126. (Canceled).

127. (Currently amended) A method of treating an affective disorder which comprises administering to a patient a therapeutically effective amount of optically pure (S,S)-2-(3-chlorophenyl)-3,5,5-trimethyl-[[3]]₂-morpholinol, or a pharmaceutically acceptable salt, solvate, hydrate, or clathrate thereof, wherein the optically pure (S,S)-2-(3-chlorophenyl)-3,5,5-trimethyl-[[3]]₂-morpholinol, or pharmaceutically acceptable salt, solvate, hydrate, or clathrate thereof, is adjunctively administered with a therapeutically effective amount of a selective serotonin reuptake inhibitor, or a pharmaceutically acceptable salt thereof;

wherein the affective disorder is an anxiety disorder, attention deficit disorder, attention deficit disorder with hyperactivity, attention deficit/hyperactivity disorder, a bipolar or manic condition, depression, or seasonal affective disorder.

128-132. (Canceled).

133. (Previously presented) The method of claim 127, wherein the selective serotonin reuptake inhibitor is citalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, or venlafaxine.